Lack of guidelines creates high rates of missed Lynch syndrome diagnosis in UTUC
“We found that while the NCCN guideline for Lynch syndrome is highly specific in identifying patients with Lynch syndrome, it missed about 50% of patients with upper tract cancer who had Lynch syndrome,” says Hong Truong, MD.
In this video, Hong Truong, MD,discusses the findings of the study, “Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Truong is a urologic oncology fellow at Memorial Sloan Kettering Cancer Center in New York, New York.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC
April 5th 2024“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
